Advertisement

Topics

Gilead Sciences, insitro Launch Up-to-$1B+ AI-Based NASH Drug Collaboration

10:13 EDT 16 Apr 2019 | Genetic Engineering News

Gilead Sciences will use the AI-based platform of insitro to discover and develop treatments for nonalcoholic steatohepatitis (NASH), the companies said today, through a collaboration that could generate more than $1 billion for the South San Francisco, CA, startup focused on drug development using machine learning and data science tools. The companies have inked a […]

The post Gilead Sciences, insitro Launch Up-to-$1B+ AI-Based NASH Drug Collaboration appeared first on GEN - Genetic Engineering and Biotechnology News.

Original Article: Gilead Sciences, insitro Launch Up-to-$1B+ AI-Based NASH Drug Collaboration

NEXT ARTICLE

More From BioPortfolio on "Gilead Sciences, insitro Launch Up-to-$1B+ AI-Based NASH Drug Collaboration"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...